Published in Cancer on September 22, 2011
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer. EMBO J (2015) 1.69
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol (2013) 1.36
Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest (2014) 1.33
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. Cancer Microenviron (2014) 1.24
Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis. PLoS One (2012) 1.13
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonist attenuate tumor growth via polarization of neutrophils toward an antitumor phenotype. Oncoimmunology (2015) 1.10
Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer. Pharmaceuticals (Basel) (2013) 1.10
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol (2013) 1.07
Neutrophils in cancer: neutral no more. Nat Rev Cancer (2016) 1.06
Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS One (2014) 1.05
Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization. J Invest Dermatol (2014) 0.97
Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer. Br J Cancer (2013) 0.96
The role of myeloid cells in cancer therapies. Nat Rev Cancer (2016) 0.92
Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology (2012) 0.91
Lessons from cancer immunoediting in cutaneous melanoma. Clin Dev Immunol (2012) 0.91
Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. J Invest Dermatol (2014) 0.91
Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90
Neutrophils in the Tumor Microenvironment. Trends Immunol (2015) 0.89
Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. Mod Pathol (2012) 0.87
Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol (2012) 0.87
Neutrophil-lymphocyte ratio as a predictor of recurrence and progression in patients with high-grade pT1 bladder cancer. Can Urol Assoc J (2015) 0.84
The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape. Front Immunol (2013) 0.83
Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Transl Med (2015) 0.81
Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity. Oncoimmunology (2014) 0.81
Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor. J Thorac Oncol (2015) 0.81
Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models. Oncoimmunology (2012) 0.80
Neutrophils Activate Tumoral CORTACTIN to Enhance Progression of Orohypopharynx Carcinoma. Front Immunol (2013) 0.80
Role of dendritic cells in the regulation of antitumor immunity. Oncoimmunology (2013) 0.79
Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer. Cancer Sci (2014) 0.78
Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy. Vaccines (Basel) (2016) 0.78
Phorbol ester-induced neutrophilic inflammatory responses selectively promote metastatic spread of melanoma in a TLR4-dependent manner. Oncoimmunology (2015) 0.77
The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance. Vaccines (Basel) (2016) 0.76
Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy? Clin Transl Immunology (2017) 0.75
Melanoma hijacks plasmacytoid dendritic cells to promote its own progression. Oncoimmunology (2014) 0.75
Melanomas and Dysplastic Nevi Differ in Epidermal CD1c+ Dendritic Cell Count. Biomed Res Int (2017) 0.75
Histamine therapeutic efficacy in metastatic melanoma: Role of histamine H4 receptor agonists and opportunity for combination with radiation. Oncotarget (2017) 0.75
Vasculogenic mimicry is associated with increased tumor-infiltrating neutrophil and poor outcome in esophageal squamous cell carcinoma. Onco Targets Ther (2017) 0.75
Role of poly(ε-caprolactone) lipid-core nanocapsules on melanoma-neutrophil crosstalk. Int J Nanomedicine (2017) 0.75
CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma. Postepy Dermatol Alergol (2017) 0.75
Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap. Trends Cancer (2017) 0.75
Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression-A Case Report from the IMMO-GLIO-01 Trial. Front Neurol (2017) 0.75
Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. Oncoimmunology (2017) 0.75
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother (2011) 4.02
Analysis of deaths related to anesthesia in the period 1996-2004 from closed claims registered by the Danish Patient Insurance Association. Anesthesiology (2007) 3.49
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. J Mol Diagn (2012) 2.53
Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: a methodological study on lymph nodes from melanoma patients. J Mol Diagn (2003) 2.41
CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med (2004) 2.33
Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol (2009) 2.13
Identification of the receptor scavenging hemopexin-heme complexes. Blood (2005) 1.97
Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol (2009) 1.84
Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. Cancer (2004) 1.53
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer (2010) 1.52
The nodal location of metastases in melanoma sentinel lymph nodes. Am J Surg Pathol (2009) 1.43
Treatment influencing down-staging in EORTC Melanoma Group sentinel node histological protocol compared with complete step-sectioning: a national multicentre study. Eur J Cancer (2011) 1.43
Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J (2006) 1.42
Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol (2003) 1.30
Deformable image registration for contour propagation from CT to cone-beam CT scans in radiotherapy of prostate cancer. Acta Oncol (2011) 1.29
Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol (2010) 1.24
High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat (2003) 1.21
Molecular characterization of the haptoglobin.hemoglobin receptor CD163. Ligand binding properties of the scavenger receptor cysteine-rich domain region. J Biol Chem (2004) 1.20
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology (2008) 1.18
Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers (2008) 1.18
Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. Radiother Oncol (2009) 1.18
Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol (2009) 1.15
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology (2009) 1.14
The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys (2004) 1.13
uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr Drug Targets (2011) 1.12
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother (2012) 1.11
Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther (2012) 1.10
The challenges of comparing a clinically validated test to other methods. J Mol Diagn (2013) 1.09
Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res (2006) 1.09
A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study. Crit Care (2007) 1.08
Interleukin-6 and melanoma. Melanoma Res (2012) 1.07
Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res (2002) 1.07
Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol (2006) 1.04
Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome. Lung Cancer (2013) 1.04
Impact of changes in bladder and rectal filling volume on organ motion and dose distribution of the bladder in radiotherapy for urinary bladder cancer. Int J Radiat Oncol Biol Phys (2004) 1.03
Robust automatic segmentation of multiple implanted cylindrical gold fiducial markers in cone-beam CT projections. Med Phys (2011) 1.03
Soluble haemoglobin scavenger receptor (sCD163) in patients with suspected community-acquired infections. APMIS (2006) 1.02
Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res (2009) 1.02
Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev (2008) 1.01
TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res (2007) 1.00
Screening for colorectal cancer: possible improvements by risk assessment evaluation? Scand J Gastroenterol (2011) 0.99
Comparison of two dose calculation methods applied to extracranial stereotactic radiotherapy treatment planning. Radiother Oncol (2005) 0.99
A fatal case of malignant atrophic papulosis (Degos' disease) in a man with factor V Leinden mutation and lupus anticoagulant. Acta Derm Venereol (2006) 0.99
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg (2013) 0.97
Inter- and intrafractional localisation errors in cone-beam CT guided stereotactic radiation therapy of tumours in the liver and lung. Acta Oncol (2010) 0.97
Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer (2012) 0.97
Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas (2012) 0.97
Residual set-up errors and margins in on-line image-guided prostate localization in radiotherapy. Radiother Oncol (2007) 0.96
Digital image analysis: a review of reproducibility, stability and basic requirements for optimal results. APMIS (2011) 0.96
A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Gynecol Oncol (2011) 0.96
Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations. Clin Chim Acta (2007) 0.96
Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol (2010) 0.96
Temporal course of pregnancy-associated plasma protein-A in angioplasty-treated ST-elevation myocardial infarction patients and potential significance of concomitant heparin administration. Am J Cardiol (2008) 0.96
K-ras mutations in sinonasal cancers in relation to wood dust exposure. BMC Cancer (2008) 0.95
High-throughput liquid-liquid extraction and LCMSMS assay for determination of circulating 25(OH) vitamin D3 and D2 in the routine clinical laboratory. Clin Chim Acta (2009) 0.95
The macrophage scavenger receptor CD163: endocytic properties of cytoplasmic tail variants. J Leukoc Biol (2006) 0.92
The influence of immunohistochemistry on mRNA recovery from microdissected frozen and formalin-fixed, paraffin-embedded sections. Diagn Mol Pathol (2004) 0.92
Validation of epithelial ovarian cancer and fallopian tube cancer and ovarian borderline tumor data in the Danish Gynecological Cancer Database. Acta Obstet Gynecol Scand (2009) 0.92
Propagation of target and organ at risk contours in radiotherapy of prostate cancer using deformable image registration. Acta Oncol (2010) 0.92
The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol (2005) 0.90
Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey. Acta Obstet Gynecol Scand (2010) 0.90
A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer. Clin Chem (2010) 0.90
Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma. Eur J Haematol (2014) 0.90
Double role of mannose-binding lectin in relation to carotid intima-media thickness in patients with rheumatoid arthritis. Mol Immunol (2009) 0.90
Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET. Acta Oncol (2010) 0.90
High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer (2008) 0.89
Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older. Cancer (2013) 0.89
Completeness of TNM cancer staging for melanoma in the Danish Cancer Registry, 2004-2009. Clin Epidemiol (2012) 0.89
The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy. Acta Oncol (2009) 0.89
ABC transporter genes and risk of type 2 diabetes: a study of 40,000 individuals from the general population. Diabetes Care (2012) 0.89
Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res (2012) 0.89
Circulating levels of the shed scavenger receptor sCD163 and association with outcome of critically ill patients. J Clin Immunol (2012) 0.89
Mutations in TP53 tumor suppressor gene in wood dust-related sinonasal cancer. Int J Cancer (2010) 0.88
Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer. Scand J Clin Lab Invest (2010) 0.88
Skin markers for Hodgkin's disease. Acta Derm Venereol (2005) 0.87
Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression. PLoS One (2008) 0.87
Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. Mod Pathol (2012) 0.87
[DaProCadata--Danish Prostate Cancer Database]. Ugeskr Laeger (2012) 0.87
Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate (2010) 0.87
Profile of TP53 gene mutations in sinonasal cancer. Mutat Res (2009) 0.87
Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications. Acta Oncol (2008) 0.87
Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS One (2013) 0.86
Concomitant lack of MMP9 and uPA disturbs physiological tissue remodeling. Dev Biol (2011) 0.86
Faecal incontinence following radiotherapy for prostate cancer: a systematic review. Radiother Oncol (2011) 0.86
Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med (2013) 0.85
Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum? Gynecol Oncol (2004) 0.85
Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA. APMIS (2002) 0.85
Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment. Radiother Oncol (2011) 0.85